nodes	percent_of_prediction	percent_of_DWPC	metapath
Regorafenib—Protein Kinase Inhibitors—Vemurafenib—skin cancer	0.331	1	CiPCiCtD
Regorafenib—Sorafenib—Vismodegib—skin cancer	0.245	1	CrCrCtD
Regorafenib—BRAF—skin cancer	0.138	1	CbGaD
Regorafenib—RAF1—Vemurafenib—skin cancer	0.0729	0.385	CbGbCtD
Regorafenib—BRAF—Vemurafenib—skin cancer	0.061	0.322	CbGbCtD
Regorafenib—ABCG2—Vismodegib—skin cancer	0.00875	0.0462	CbGbCtD
Regorafenib—ABCG2—Vemurafenib—skin cancer	0.00692	0.0365	CbGbCtD
Regorafenib—CYP2C8—Vismodegib—skin cancer	0.00466	0.0246	CbGbCtD
Regorafenib—ABCG2—Dactinomycin—skin cancer	0.0046	0.0243	CbGbCtD
Regorafenib—CYP2C19—Vismodegib—skin cancer	0.00391	0.0207	CbGbCtD
Regorafenib—CYP2C9—Vismodegib—skin cancer	0.00325	0.0172	CbGbCtD
Regorafenib—ABCB1—Vismodegib—skin cancer	0.00315	0.0167	CbGbCtD
Regorafenib—ABCG2—Fluorouracil—skin cancer	0.00311	0.0164	CbGbCtD
Regorafenib—CYP3A4—Imiquimod—skin cancer	0.00273	0.0144	CbGbCtD
Regorafenib—CYP3A4—Temozolomide—skin cancer	0.00273	0.0144	CbGbCtD
Regorafenib—ABCG2—Docetaxel—skin cancer	0.00237	0.0125	CbGbCtD
Regorafenib—CYP3A4—Vismodegib—skin cancer	0.00189	0.00999	CbGbCtD
Regorafenib—ABCB1—Dactinomycin—skin cancer	0.00166	0.00875	CbGbCtD
Regorafenib—CYP2C8—Fluorouracil—skin cancer	0.00166	0.00874	CbGbCtD
Regorafenib—CYP3A4—Vemurafenib—skin cancer	0.00149	0.00789	CbGbCtD
Regorafenib—CYP2C9—Fluorouracil—skin cancer	0.00115	0.0061	CbGbCtD
Regorafenib—DDR2—skin epidermis—skin cancer	0.00103	0.0412	CbGeAlD
Regorafenib—Sorafenib—BRAF—skin cancer	0.000907	1	CrCbGaD
Regorafenib—ABCB1—Docetaxel—skin cancer	0.000856	0.00452	CbGbCtD
Regorafenib—PDGFRA—penis—skin cancer	0.000853	0.034	CbGeAlD
Regorafenib—DDR2—hair follicle—skin cancer	0.000738	0.0294	CbGeAlD
Regorafenib—KDR—hindlimb—skin cancer	0.000581	0.0231	CbGeAlD
Regorafenib—FGFR2—skin epidermis—skin cancer	0.000529	0.0211	CbGeAlD
Regorafenib—CYP3A4—Docetaxel—skin cancer	0.000513	0.00271	CbGbCtD
Regorafenib—KDR—appendage—skin cancer	0.000498	0.0199	CbGeAlD
Regorafenib—FLT4—endothelium—skin cancer	0.000457	0.0182	CbGeAlD
Regorafenib—FLT4—blood vessel—skin cancer	0.000422	0.0168	CbGeAlD
Regorafenib—TEK—endothelium—skin cancer	0.000368	0.0147	CbGeAlD
Regorafenib—KIT—skin epidermis—skin cancer	0.000367	0.0146	CbGeAlD
Regorafenib—FLT1—endothelium—skin cancer	0.000356	0.0142	CbGeAlD
Regorafenib—DDR2—connective tissue—skin cancer	0.000355	0.0142	CbGeAlD
Regorafenib—EPHA2—blood vessel—skin cancer	0.000348	0.0139	CbGeAlD
Regorafenib—RAF1—hair follicle—skin cancer	0.000348	0.0139	CbGeAlD
Regorafenib—TEK—blood vessel—skin cancer	0.000339	0.0135	CbGeAlD
Regorafenib—FLT1—blood vessel—skin cancer	0.000328	0.0131	CbGeAlD
Regorafenib—DDR2—skin of body—skin cancer	0.000321	0.0128	CbGeAlD
Regorafenib—KDR—endothelium—skin cancer	0.000301	0.012	CbGeAlD
Regorafenib—DDR2—mammalian vulva—skin cancer	0.000292	0.0117	CbGeAlD
Regorafenib—FRK—lymphoid tissue—skin cancer	0.000289	0.0115	CbGeAlD
Regorafenib—FRK—female reproductive system—skin cancer	0.000279	0.0111	CbGeAlD
Regorafenib—KDR—blood vessel—skin cancer	0.000277	0.0111	CbGeAlD
Regorafenib—KIT—endothelium—skin cancer	0.000266	0.0106	CbGeAlD
Regorafenib—RET—neck—skin cancer	0.000266	0.0106	CbGeAlD
Regorafenib—DDR2—lymphoid tissue—skin cancer	0.00026	0.0103	CbGeAlD
Regorafenib—FGFR2—neck—skin cancer	0.000253	0.0101	CbGeAlD
Regorafenib—EPHA2—nipple—skin cancer	0.000251	0.01	CbGeAlD
Regorafenib—DDR2—female reproductive system—skin cancer	0.00025	0.00998	CbGeAlD
Regorafenib—KIT—blood vessel—skin cancer	0.000246	0.00979	CbGeAlD
Regorafenib—PDGFRB—blood vessel—skin cancer	0.00024	0.00957	CbGeAlD
Regorafenib—MAPK11—female reproductive system—skin cancer	0.000237	0.00946	CbGeAlD
Regorafenib—FLT1—nipple—skin cancer	0.000237	0.00945	CbGeAlD
Regorafenib—RAF1—nipple—skin cancer	0.000236	0.0094	CbGeAlD
Regorafenib—FLT1—neck—skin cancer	0.000235	0.00935	CbGeAlD
Regorafenib—RAF1—neck—skin cancer	0.000233	0.0093	CbGeAlD
Regorafenib—DDR2—head—skin cancer	0.000209	0.00834	CbGeAlD
Regorafenib—FLT4—epithelium—skin cancer	0.000205	0.00818	CbGeAlD
Regorafenib—KDR—nipple—skin cancer	0.0002	0.00799	CbGeAlD
Regorafenib—KDR—neck—skin cancer	0.000198	0.00791	CbGeAlD
Regorafenib—MAPK11—head—skin cancer	0.000198	0.0079	CbGeAlD
Regorafenib—EPHX2—mammalian vulva—skin cancer	0.000198	0.00787	CbGeAlD
Regorafenib—RET—connective tissue—skin cancer	0.000191	0.00761	CbGeAlD
Regorafenib—Mucosal inflammation—Docetaxel—skin cancer	0.000183	0.00511	CcSEcCtD
Regorafenib—FGFR2—connective tissue—skin cancer	0.000181	0.00723	CbGeAlD
Regorafenib—RET—epithelium—skin cancer	0.000181	0.00723	CbGeAlD
Regorafenib—Liver injury—Temozolomide—skin cancer	0.000181	0.00506	CcSEcCtD
Regorafenib—Unspecified disorder of skin and subcutaneous tissue—Vismodegib—skin cancer	0.000178	0.00498	CcSEcCtD
Regorafenib—KIT—nipple—skin cancer	0.000178	0.00708	CbGeAlD
Regorafenib—KIT—neck—skin cancer	0.000176	0.00701	CbGeAlD
Regorafenib—FGFR1—mammalian vulva—skin cancer	0.000176	0.007	CbGeAlD
Regorafenib—Myocardial ischaemia—Fluorouracil—skin cancer	0.000175	0.00488	CcSEcCtD
Regorafenib—TEK—connective tissue—skin cancer	0.000174	0.00693	CbGeAlD
Regorafenib—PDGFRB—nipple—skin cancer	0.000174	0.00692	CbGeAlD
Regorafenib—FGFR2—epithelium—skin cancer	0.000172	0.00687	CbGeAlD
Regorafenib—PDGFRB—neck—skin cancer	0.000172	0.00684	CbGeAlD
Regorafenib—EPHA2—epithelium—skin cancer	0.000169	0.00675	CbGeAlD
Regorafenib—Weight decreased—Vemurafenib—skin cancer	0.000169	0.00473	CcSEcCtD
Regorafenib—Nervous system disorder—Vismodegib—skin cancer	0.000169	0.00472	CcSEcCtD
Regorafenib—FLT1—connective tissue—skin cancer	0.000168	0.0067	CbGeAlD
Regorafenib—Hyperbilirubinaemia—Temozolomide—skin cancer	0.000167	0.00468	CcSEcCtD
Regorafenib—RAF1—connective tissue—skin cancer	0.000167	0.00666	CbGeAlD
Regorafenib—Skin disorder—Vismodegib—skin cancer	0.000167	0.00467	CcSEcCtD
Regorafenib—Infestation NOS—Vemurafenib—skin cancer	0.000167	0.00466	CcSEcCtD
Regorafenib—Infestation—Vemurafenib—skin cancer	0.000167	0.00466	CcSEcCtD
Regorafenib—Polyp—Docetaxel—skin cancer	0.000166	0.00465	CcSEcCtD
Regorafenib—Stevens-Johnson syndrome—Vemurafenib—skin cancer	0.000165	0.00462	CcSEcCtD
Regorafenib—TEK—epithelium—skin cancer	0.000165	0.00658	CbGeAlD
Regorafenib—FGFR2—skin of body—skin cancer	0.000164	0.00653	CbGeAlD
Regorafenib—FLT1—epithelium—skin cancer	0.00016	0.00636	CbGeAlD
Regorafenib—RAF1—epithelium—skin cancer	0.000159	0.00633	CbGeAlD
Regorafenib—FLT4—lymphoid tissue—skin cancer	0.000158	0.0063	CbGeAlD
Regorafenib—PDGFRA—connective tissue—skin cancer	0.000158	0.00628	CbGeAlD
Regorafenib—Nail disorder—Docetaxel—skin cancer	0.000156	0.00436	CcSEcCtD
Regorafenib—ABL1—nipple—skin cancer	0.000155	0.00616	CbGeAlD
Regorafenib—FLT4—female reproductive system—skin cancer	0.000153	0.00608	CbGeAlD
Regorafenib—Cyst—Docetaxel—skin cancer	0.000151	0.00423	CcSEcCtD
Regorafenib—RAF1—skin of body—skin cancer	0.000151	0.00602	CbGeAlD
Regorafenib—Decreased appetite—Vismodegib—skin cancer	0.00015	0.00418	CcSEcCtD
Regorafenib—Gastrointestinal disorder—Vismodegib—skin cancer	0.000149	0.00415	CcSEcCtD
Regorafenib—Fatigue—Vismodegib—skin cancer	0.000148	0.00415	CcSEcCtD
Regorafenib—Pain—Vismodegib—skin cancer	0.000147	0.00411	CcSEcCtD
Regorafenib—Connective tissue disorder—Vemurafenib—skin cancer	0.000147	0.00411	CcSEcCtD
Regorafenib—EPHA2—mammalian vulva—skin cancer	0.000147	0.00585	CbGeAlD
Regorafenib—DDR2—lymph node—skin cancer	0.000146	0.00584	CbGeAlD
Regorafenib—KDR—connective tissue—skin cancer	0.000142	0.00567	CbGeAlD
Regorafenib—Infestation NOS—Imiquimod—skin cancer	0.000142	0.00397	CcSEcCtD
Regorafenib—Infestation—Imiquimod—skin cancer	0.000142	0.00397	CcSEcCtD
Regorafenib—Erythema multiforme—Vemurafenib—skin cancer	0.000141	0.00395	CcSEcCtD
Regorafenib—Stevens-Johnson syndrome—Imiquimod—skin cancer	0.000141	0.00394	CcSEcCtD
Regorafenib—Gastrointestinal pain—Vismodegib—skin cancer	0.000141	0.00393	CcSEcCtD
Regorafenib—Acute coronary syndrome—Imiquimod—skin cancer	0.00014	0.00392	CcSEcCtD
Regorafenib—RET—lymphoid tissue—skin cancer	0.00014	0.00557	CbGeAlD
Regorafenib—Myocardial infarction—Imiquimod—skin cancer	0.000139	0.0039	CcSEcCtD
Regorafenib—MAPK11—lymph node—skin cancer	0.000139	0.00553	CbGeAlD
Regorafenib—Cardiac disorder—Vemurafenib—skin cancer	0.000139	0.00388	CcSEcCtD
Regorafenib—FLT1—mammalian vulva—skin cancer	0.000139	0.00552	CbGeAlD
Regorafenib—RAF1—mammalian vulva—skin cancer	0.000138	0.00549	CbGeAlD
Regorafenib—Neoplasm—Temozolomide—skin cancer	0.000138	0.00385	CcSEcCtD
Regorafenib—Abdominal pain—Vismodegib—skin cancer	0.000136	0.0038	CcSEcCtD
Regorafenib—Angiopathy—Vemurafenib—skin cancer	0.000136	0.0038	CcSEcCtD
Regorafenib—KDR—epithelium—skin cancer	0.000135	0.00538	CbGeAlD
Regorafenib—Mediastinal disorder—Vemurafenib—skin cancer	0.000135	0.00377	CcSEcCtD
Regorafenib—Hepatobiliary disease—Imiquimod—skin cancer	0.000134	0.00376	CcSEcCtD
Regorafenib—Alopecia—Vemurafenib—skin cancer	0.000132	0.0037	CcSEcCtD
Regorafenib—Hepatotoxicity—Docetaxel—skin cancer	0.000131	0.00367	CcSEcCtD
Regorafenib—EPHA2—lymphoid tissue—skin cancer	0.00013	0.0052	CbGeAlD
Regorafenib—Malnutrition—Vemurafenib—skin cancer	0.00013	0.00364	CcSEcCtD
Regorafenib—Haemoglobin—Imiquimod—skin cancer	0.000128	0.00359	CcSEcCtD
Regorafenib—FGFR2—female reproductive system—skin cancer	0.000128	0.0051	CbGeAlD
Regorafenib—Haemorrhage—Imiquimod—skin cancer	0.000128	0.00357	CcSEcCtD
Regorafenib—FLT4—head—skin cancer	0.000127	0.00508	CbGeAlD
Regorafenib—TEK—lymphoid tissue—skin cancer	0.000127	0.00507	CbGeAlD
Regorafenib—Urinary tract disorder—Imiquimod—skin cancer	0.000126	0.00352	CcSEcCtD
Regorafenib—KIT—connective tissue—skin cancer	0.000126	0.00502	CbGeAlD
Regorafenib—Myocardial ischaemia—Docetaxel—skin cancer	0.000126	0.00352	CcSEcCtD
Regorafenib—EPHA2—female reproductive system—skin cancer	0.000126	0.00501	CbGeAlD
Regorafenib—Connective tissue disorder—Imiquimod—skin cancer	0.000125	0.00351	CcSEcCtD
Regorafenib—Urethral disorder—Imiquimod—skin cancer	0.000125	0.0035	CcSEcCtD
Regorafenib—Gastroenteritis—Temozolomide—skin cancer	0.000125	0.00349	CcSEcCtD
Regorafenib—Asthenia—Vismodegib—skin cancer	0.000123	0.00345	CcSEcCtD
Regorafenib—PDGFRB—connective tissue—skin cancer	0.000123	0.0049	CbGeAlD
Regorafenib—FLT1—lymphoid tissue—skin cancer	0.000123	0.0049	CbGeAlD
Regorafenib—TEK—female reproductive system—skin cancer	0.000123	0.00489	CbGeAlD
Regorafenib—RAF1—lymphoid tissue—skin cancer	0.000122	0.00487	CbGeAlD
Regorafenib—Erythema multiforme—Imiquimod—skin cancer	0.000121	0.00337	CcSEcCtD
Regorafenib—KIT—epithelium—skin cancer	0.00012	0.00477	CbGeAlD
Regorafenib—FLT1—female reproductive system—skin cancer	0.000119	0.00473	CbGeAlD
Regorafenib—RAF1—female reproductive system—skin cancer	0.000118	0.0047	CbGeAlD
Regorafenib—Diarrhoea—Vismodegib—skin cancer	0.000118	0.00329	CcSEcCtD
Regorafenib—KDR—mammalian vulva—skin cancer	0.000117	0.00467	CbGeAlD
Regorafenib—PDGFRB—epithelium—skin cancer	0.000117	0.00466	CbGeAlD
Regorafenib—Angiopathy—Imiquimod—skin cancer	0.000116	0.00324	CcSEcCtD
Regorafenib—PDGFRA—lymphoid tissue—skin cancer	0.000115	0.00459	CbGeAlD
Regorafenib—Mediastinal disorder—Imiquimod—skin cancer	0.000115	0.00321	CcSEcCtD
Regorafenib—KIT—skin of body—skin cancer	0.000114	0.00453	CbGeAlD
Regorafenib—Alopecia—Imiquimod—skin cancer	0.000113	0.00315	CcSEcCtD
Regorafenib—RET—head—skin cancer	0.000113	0.00448	CbGeAlD
Regorafenib—Hyperbilirubinaemia—Docetaxel—skin cancer	0.000111	0.00311	CcSEcCtD
Regorafenib—PDGFRA—female reproductive system—skin cancer	0.000111	0.00443	CbGeAlD
Regorafenib—PDGFRB—skin of body—skin cancer	0.000111	0.00443	CbGeAlD
Regorafenib—Malnutrition—Imiquimod—skin cancer	0.000111	0.00311	CcSEcCtD
Regorafenib—Unspecified disorder of skin and subcutaneous tissue—Vemurafenib—skin cancer	0.00011	0.00308	CcSEcCtD
Regorafenib—Toxic epidermal necrolysis—Dactinomycin—skin cancer	0.00011	0.00308	CcSEcCtD
Regorafenib—Aspartate aminotransferase increased—Dactinomycin—skin cancer	0.00011	0.00308	CcSEcCtD
Regorafenib—ABL1—connective tissue—skin cancer	0.00011	0.00437	CbGeAlD
Regorafenib—Vomiting—Vismodegib—skin cancer	0.000109	0.00306	CcSEcCtD
Regorafenib—Rash—Vismodegib—skin cancer	0.000108	0.00303	CcSEcCtD
Regorafenib—Dermatitis—Vismodegib—skin cancer	0.000108	0.00303	CcSEcCtD
Regorafenib—FGFR2—head—skin cancer	0.000107	0.00426	CbGeAlD
Regorafenib—Infection—Vemurafenib—skin cancer	0.000106	0.00295	CcSEcCtD
Regorafenib—EPHA2—head—skin cancer	0.000105	0.00419	CbGeAlD
Regorafenib—Nervous system disorder—Vemurafenib—skin cancer	0.000104	0.00291	CcSEcCtD
Regorafenib—KDR—lymphoid tissue—skin cancer	0.000104	0.00414	CbGeAlD
Regorafenib—KIT—mammalian vulva—skin cancer	0.000104	0.00414	CbGeAlD
Regorafenib—BRAF—lymph node—skin cancer	0.000104	0.00413	CbGeAlD
Regorafenib—Skin disorder—Vemurafenib—skin cancer	0.000103	0.00289	CcSEcCtD
Regorafenib—TEK—head—skin cancer	0.000102	0.00408	CbGeAlD
Regorafenib—Weight decreased—Bleomycin—skin cancer	0.000102	0.00286	CcSEcCtD
Regorafenib—Nausea—Vismodegib—skin cancer	0.000102	0.00286	CcSEcCtD
Regorafenib—PDGFRB—mammalian vulva—skin cancer	0.000101	0.00404	CbGeAlD
Regorafenib—Dry skin—Temozolomide—skin cancer	0.000101	0.00283	CcSEcCtD
Regorafenib—Hypokalaemia—Temozolomide—skin cancer	0.000101	0.00281	CcSEcCtD
Regorafenib—KDR—female reproductive system—skin cancer	0.0001	0.004	CbGeAlD
Regorafenib—Acute coronary syndrome—Bleomycin—skin cancer	9.95e-05	0.00278	CcSEcCtD
Regorafenib—Toxic epidermal necrolysis—Temozolomide—skin cancer	9.95e-05	0.00278	CcSEcCtD
Regorafenib—Aspartate aminotransferase increased—Temozolomide—skin cancer	9.95e-05	0.00278	CcSEcCtD
Regorafenib—FLT1—head—skin cancer	9.91e-05	0.00395	CbGeAlD
Regorafenib—ABL1—skin of body—skin cancer	9.9e-05	0.00395	CbGeAlD
Regorafenib—Myocardial infarction—Bleomycin—skin cancer	9.9e-05	0.00277	CcSEcCtD
Regorafenib—EPHX2—lymph node—skin cancer	9.9e-05	0.00394	CbGeAlD
Regorafenib—Neutropenia—Dactinomycin—skin cancer	9.88e-05	0.00276	CcSEcCtD
Regorafenib—RAF1—head—skin cancer	9.85e-05	0.00393	CbGeAlD
Regorafenib—Stomatitis—Bleomycin—skin cancer	9.84e-05	0.00275	CcSEcCtD
Regorafenib—Alanine aminotransferase increased—Temozolomide—skin cancer	9.75e-05	0.00273	CcSEcCtD
Regorafenib—Hypertension—Imiquimod—skin cancer	9.59e-05	0.00268	CcSEcCtD
Regorafenib—Unspecified disorder of skin and subcutaneous tissue—Imiquimod—skin cancer	9.39e-05	0.00263	CcSEcCtD
Regorafenib—Stevens-Johnson syndrome—Dactinomycin—skin cancer	9.34e-05	0.00261	CcSEcCtD
Regorafenib—Dry skin—Fluorouracil—skin cancer	9.34e-05	0.00261	CcSEcCtD
Regorafenib—PDGFRA—head—skin cancer	9.29e-05	0.0037	CbGeAlD
Regorafenib—Dry mouth—Imiquimod—skin cancer	9.25e-05	0.00259	CcSEcCtD
Regorafenib—Decreased appetite—Vemurafenib—skin cancer	9.24e-05	0.00258	CcSEcCtD
Regorafenib—KIT—lymphoid tissue—skin cancer	9.21e-05	0.00367	CbGeAlD
Regorafenib—Stomatitis—Dactinomycin—skin cancer	9.18e-05	0.00257	CcSEcCtD
Regorafenib—Gastrointestinal disorder—Vemurafenib—skin cancer	9.18e-05	0.00257	CcSEcCtD
Regorafenib—Fatigue—Vemurafenib—skin cancer	9.16e-05	0.00256	CcSEcCtD
Regorafenib—Neoplasm—Docetaxel—skin cancer	9.16e-05	0.00256	CcSEcCtD
Regorafenib—Haemoglobin—Bleomycin—skin cancer	9.11e-05	0.00255	CcSEcCtD
Regorafenib—Haemorrhage—Bleomycin—skin cancer	9.07e-05	0.00253	CcSEcCtD
Regorafenib—ABL1—mammalian vulva—skin cancer	9.03e-05	0.0036	CbGeAlD
Regorafenib—Infection—Imiquimod—skin cancer	9.01e-05	0.00252	CcSEcCtD
Regorafenib—PDGFRB—lymphoid tissue—skin cancer	9e-05	0.00359	CbGeAlD
Regorafenib—Neutropenia—Temozolomide—skin cancer	8.93e-05	0.0025	CcSEcCtD
Regorafenib—FLT4—lymph node—skin cancer	8.92e-05	0.00356	CbGeAlD
Regorafenib—Nervous system disorder—Imiquimod—skin cancer	8.89e-05	0.00249	CcSEcCtD
Regorafenib—KIT—female reproductive system—skin cancer	8.89e-05	0.00354	CbGeAlD
Regorafenib—Skin disorder—Imiquimod—skin cancer	8.81e-05	0.00246	CcSEcCtD
Regorafenib—FGFR1—lymph node—skin cancer	8.8e-05	0.00351	CbGeAlD
Regorafenib—PDGFRB—female reproductive system—skin cancer	8.68e-05	0.00346	CbGeAlD
Regorafenib—Weight decreased—Temozolomide—skin cancer	8.64e-05	0.00242	CcSEcCtD
Regorafenib—Infestation—Temozolomide—skin cancer	8.52e-05	0.00238	CcSEcCtD
Regorafenib—Infestation NOS—Temozolomide—skin cancer	8.52e-05	0.00238	CcSEcCtD
Regorafenib—Stevens-Johnson syndrome—Temozolomide—skin cancer	8.44e-05	0.00236	CcSEcCtD
Regorafenib—Body temperature increased—Vemurafenib—skin cancer	8.4e-05	0.00235	CcSEcCtD
Regorafenib—KDR—head—skin cancer	8.38e-05	0.00334	CbGeAlD
Regorafenib—Stomatitis—Temozolomide—skin cancer	8.3e-05	0.00232	CcSEcCtD
Regorafenib—Hepatobiliary disease—Temozolomide—skin cancer	8.06e-05	0.00225	CcSEcCtD
Regorafenib—ABL1—lymphoid tissue—skin cancer	8.02e-05	0.0032	CbGeAlD
Regorafenib—Alopecia—Bleomycin—skin cancer	8.01e-05	0.00224	CcSEcCtD
Regorafenib—Erythema multiforme—Dactinomycin—skin cancer	7.99e-05	0.00223	CcSEcCtD
Regorafenib—Decreased appetite—Imiquimod—skin cancer	7.88e-05	0.0022	CcSEcCtD
Regorafenib—RET—lymph node—skin cancer	7.88e-05	0.00314	CbGeAlD
Regorafenib—Infestation NOS—Fluorouracil—skin cancer	7.85e-05	0.00219	CcSEcCtD
Regorafenib—Infestation—Fluorouracil—skin cancer	7.85e-05	0.00219	CcSEcCtD
Regorafenib—Gastrointestinal disorder—Imiquimod—skin cancer	7.83e-05	0.00219	CcSEcCtD
Regorafenib—Fatigue—Imiquimod—skin cancer	7.82e-05	0.00219	CcSEcCtD
Regorafenib—Pain—Imiquimod—skin cancer	7.75e-05	0.00217	CcSEcCtD
Regorafenib—Acute coronary syndrome—Fluorouracil—skin cancer	7.74e-05	0.00216	CcSEcCtD
Regorafenib—ABL1—female reproductive system—skin cancer	7.74e-05	0.00308	CbGeAlD
Regorafenib—Myocardial infarction—Fluorouracil—skin cancer	7.69e-05	0.00215	CcSEcCtD
Regorafenib—Haemoglobin—Temozolomide—skin cancer	7.69e-05	0.00215	CcSEcCtD
Regorafenib—Stomatitis—Fluorouracil—skin cancer	7.65e-05	0.00214	CcSEcCtD
Regorafenib—Haemorrhage—Temozolomide—skin cancer	7.65e-05	0.00214	CcSEcCtD
Regorafenib—Asthenia—Vemurafenib—skin cancer	7.63e-05	0.00213	CcSEcCtD
Regorafenib—Urinary tract disorder—Temozolomide—skin cancer	7.55e-05	0.00211	CcSEcCtD
Regorafenib—Connective tissue disorder—Temozolomide—skin cancer	7.51e-05	0.0021	CcSEcCtD
Regorafenib—Urethral disorder—Temozolomide—skin cancer	7.5e-05	0.0021	CcSEcCtD
Regorafenib—Alopecia—Dactinomycin—skin cancer	7.47e-05	0.00209	CcSEcCtD
Regorafenib—KIT—head—skin cancer	7.42e-05	0.00296	CbGeAlD
Regorafenib—Gastrointestinal pain—Imiquimod—skin cancer	7.41e-05	0.00207	CcSEcCtD
Regorafenib—Hyponatraemia—Docetaxel—skin cancer	7.38e-05	0.00206	CcSEcCtD
Regorafenib—EPHA2—lymph node—skin cancer	7.36e-05	0.00293	CbGeAlD
Regorafenib—Anaemia—Bleomycin—skin cancer	7.29e-05	0.00204	CcSEcCtD
Regorafenib—Diarrhoea—Vemurafenib—skin cancer	7.27e-05	0.00203	CcSEcCtD
Regorafenib—PDGFRB—head—skin cancer	7.25e-05	0.00289	CbGeAlD
Regorafenib—Erythema multiforme—Temozolomide—skin cancer	7.23e-05	0.00202	CcSEcCtD
Regorafenib—TEK—lymph node—skin cancer	7.18e-05	0.00286	CbGeAlD
Regorafenib—Abdominal pain—Imiquimod—skin cancer	7.17e-05	0.002	CcSEcCtD
Regorafenib—Body temperature increased—Imiquimod—skin cancer	7.17e-05	0.002	CcSEcCtD
Regorafenib—Cardiac disorder—Temozolomide—skin cancer	7.1e-05	0.00198	CcSEcCtD
Regorafenib—Haemoglobin—Fluorouracil—skin cancer	7.08e-05	0.00198	CcSEcCtD
Regorafenib—Leukopenia—Bleomycin—skin cancer	7.06e-05	0.00197	CcSEcCtD
Regorafenib—Haemorrhage—Fluorouracil—skin cancer	7.05e-05	0.00197	CcSEcCtD
Regorafenib—FLT1—lymph node—skin cancer	6.94e-05	0.00277	CbGeAlD
Regorafenib—Angiopathy—Temozolomide—skin cancer	6.94e-05	0.00194	CcSEcCtD
Regorafenib—RAF1—lymph node—skin cancer	6.9e-05	0.00275	CbGeAlD
Regorafenib—Mediastinal disorder—Temozolomide—skin cancer	6.89e-05	0.00193	CcSEcCtD
Regorafenib—Anaemia—Dactinomycin—skin cancer	6.8e-05	0.0019	CcSEcCtD
Regorafenib—Vomiting—Vemurafenib—skin cancer	6.76e-05	0.00189	CcSEcCtD
Regorafenib—Alopecia—Temozolomide—skin cancer	6.76e-05	0.00189	CcSEcCtD
Regorafenib—Dry skin—Docetaxel—skin cancer	6.74e-05	0.00188	CcSEcCtD
Regorafenib—Rash—Vemurafenib—skin cancer	6.7e-05	0.00187	CcSEcCtD
Regorafenib—Dermatitis—Vemurafenib—skin cancer	6.7e-05	0.00187	CcSEcCtD
Regorafenib—Headache—Vemurafenib—skin cancer	6.66e-05	0.00186	CcSEcCtD
Regorafenib—Malnutrition—Temozolomide—skin cancer	6.66e-05	0.00186	CcSEcCtD
Regorafenib—ABCB1—blood vessel—skin cancer	6.65e-05	0.00265	CbGeAlD
Regorafenib—Toxic epidermal necrolysis—Docetaxel—skin cancer	6.62e-05	0.00185	CcSEcCtD
Regorafenib—Aspartate aminotransferase increased—Docetaxel—skin cancer	6.62e-05	0.00185	CcSEcCtD
Regorafenib—Leukopenia—Dactinomycin—skin cancer	6.59e-05	0.00184	CcSEcCtD
Regorafenib—Asthenia—Imiquimod—skin cancer	6.5e-05	0.00182	CcSEcCtD
Regorafenib—PDGFRA—lymph node—skin cancer	6.5e-05	0.00259	CbGeAlD
Regorafenib—Alanine aminotransferase increased—Docetaxel—skin cancer	6.48e-05	0.00181	CcSEcCtD
Regorafenib—ABL1—head—skin cancer	6.46e-05	0.00258	CbGeAlD
Regorafenib—Infection—Bleomycin—skin cancer	6.4e-05	0.00179	CcSEcCtD
Regorafenib—Nausea—Vemurafenib—skin cancer	6.31e-05	0.00177	CcSEcCtD
Regorafenib—Thrombocytopenia—Bleomycin—skin cancer	6.31e-05	0.00176	CcSEcCtD
Regorafenib—Tremor—Temozolomide—skin cancer	6.24e-05	0.00174	CcSEcCtD
Regorafenib—Alopecia—Fluorouracil—skin cancer	6.23e-05	0.00174	CcSEcCtD
Regorafenib—Diarrhoea—Imiquimod—skin cancer	6.2e-05	0.00173	CcSEcCtD
Regorafenib—Anaemia—Temozolomide—skin cancer	6.15e-05	0.00172	CcSEcCtD
Regorafenib—Infection—Dactinomycin—skin cancer	5.97e-05	0.00167	CcSEcCtD
Regorafenib—Leukopenia—Temozolomide—skin cancer	5.96e-05	0.00167	CcSEcCtD
Regorafenib—Neutropenia—Docetaxel—skin cancer	5.94e-05	0.00166	CcSEcCtD
Regorafenib—Thrombocytopenia—Dactinomycin—skin cancer	5.88e-05	0.00164	CcSEcCtD
Regorafenib—KDR—lymph node—skin cancer	5.87e-05	0.00234	CbGeAlD
Regorafenib—Vomiting—Imiquimod—skin cancer	5.76e-05	0.00161	CcSEcCtD
Regorafenib—CYP2B6—skin of body—skin cancer	5.76e-05	0.0023	CbGeAlD
Regorafenib—Weight decreased—Docetaxel—skin cancer	5.75e-05	0.00161	CcSEcCtD
Regorafenib—Hypertension—Temozolomide—skin cancer	5.75e-05	0.00161	CcSEcCtD
Regorafenib—Rash—Imiquimod—skin cancer	5.72e-05	0.0016	CcSEcCtD
Regorafenib—Dermatitis—Imiquimod—skin cancer	5.71e-05	0.0016	CcSEcCtD
Regorafenib—ABCG2—mammalian vulva—skin cancer	5.7e-05	0.00227	CbGeAlD
Regorafenib—Headache—Imiquimod—skin cancer	5.68e-05	0.00159	CcSEcCtD
Regorafenib—Anaemia—Fluorouracil—skin cancer	5.67e-05	0.00158	CcSEcCtD
Regorafenib—Infestation NOS—Docetaxel—skin cancer	5.66e-05	0.00158	CcSEcCtD
Regorafenib—Infestation—Docetaxel—skin cancer	5.66e-05	0.00158	CcSEcCtD
Regorafenib—Unspecified disorder of skin and subcutaneous tissue—Temozolomide—skin cancer	5.63e-05	0.00157	CcSEcCtD
Regorafenib—Stevens-Johnson syndrome—Docetaxel—skin cancer	5.62e-05	0.00157	CcSEcCtD
Regorafenib—Decreased appetite—Bleomycin—skin cancer	5.6e-05	0.00157	CcSEcCtD
Regorafenib—Acute coronary syndrome—Docetaxel—skin cancer	5.58e-05	0.00156	CcSEcCtD
Regorafenib—Myocardial infarction—Docetaxel—skin cancer	5.55e-05	0.00155	CcSEcCtD
Regorafenib—Dry mouth—Temozolomide—skin cancer	5.54e-05	0.00155	CcSEcCtD
Regorafenib—Stomatitis—Docetaxel—skin cancer	5.52e-05	0.00154	CcSEcCtD
Regorafenib—Pain—Bleomycin—skin cancer	5.51e-05	0.00154	CcSEcCtD
Regorafenib—Leukopenia—Fluorouracil—skin cancer	5.49e-05	0.00153	CcSEcCtD
Regorafenib—Infection—Temozolomide—skin cancer	5.4e-05	0.00151	CcSEcCtD
Regorafenib—Nausea—Imiquimod—skin cancer	5.38e-05	0.00151	CcSEcCtD
Regorafenib—Hepatobiliary disease—Docetaxel—skin cancer	5.36e-05	0.0015	CcSEcCtD
Regorafenib—Nervous system disorder—Temozolomide—skin cancer	5.33e-05	0.00149	CcSEcCtD
Regorafenib—Thrombocytopenia—Temozolomide—skin cancer	5.32e-05	0.00149	CcSEcCtD
Regorafenib—Skin disorder—Temozolomide—skin cancer	5.28e-05	0.00148	CcSEcCtD
Regorafenib—Decreased appetite—Dactinomycin—skin cancer	5.22e-05	0.00146	CcSEcCtD
Regorafenib—KIT—lymph node—skin cancer	5.2e-05	0.00207	CbGeAlD
Regorafenib—Fatigue—Dactinomycin—skin cancer	5.18e-05	0.00145	CcSEcCtD
Regorafenib—Pain—Dactinomycin—skin cancer	5.14e-05	0.00144	CcSEcCtD
Regorafenib—Haemoglobin—Docetaxel—skin cancer	5.11e-05	0.00143	CcSEcCtD
Regorafenib—Body temperature increased—Bleomycin—skin cancer	5.09e-05	0.00142	CcSEcCtD
Regorafenib—Haemorrhage—Docetaxel—skin cancer	5.09e-05	0.00142	CcSEcCtD
Regorafenib—PDGFRB—lymph node—skin cancer	5.08e-05	0.00202	CbGeAlD
Regorafenib—Urinary tract disorder—Docetaxel—skin cancer	5.02e-05	0.0014	CcSEcCtD
Regorafenib—CYP2C8—female reproductive system—skin cancer	5.02e-05	0.002	CbGeAlD
Regorafenib—Connective tissue disorder—Docetaxel—skin cancer	5e-05	0.0014	CcSEcCtD
Regorafenib—Urethral disorder—Docetaxel—skin cancer	4.98e-05	0.00139	CcSEcCtD
Regorafenib—Infection—Fluorouracil—skin cancer	4.97e-05	0.00139	CcSEcCtD
Regorafenib—Gastrointestinal pain—Dactinomycin—skin cancer	4.91e-05	0.00137	CcSEcCtD
Regorafenib—Nervous system disorder—Fluorouracil—skin cancer	4.91e-05	0.00137	CcSEcCtD
Regorafenib—Thrombocytopenia—Fluorouracil—skin cancer	4.9e-05	0.00137	CcSEcCtD
Regorafenib—Erythema multiforme—Docetaxel—skin cancer	4.81e-05	0.00134	CcSEcCtD
Regorafenib—Abdominal pain—Dactinomycin—skin cancer	4.75e-05	0.00133	CcSEcCtD
Regorafenib—Body temperature increased—Dactinomycin—skin cancer	4.75e-05	0.00133	CcSEcCtD
Regorafenib—Decreased appetite—Temozolomide—skin cancer	4.72e-05	0.00132	CcSEcCtD
Regorafenib—Cardiac disorder—Docetaxel—skin cancer	4.72e-05	0.00132	CcSEcCtD
Regorafenib—Gastrointestinal disorder—Temozolomide—skin cancer	4.69e-05	0.00131	CcSEcCtD
Regorafenib—Fatigue—Temozolomide—skin cancer	4.68e-05	0.00131	CcSEcCtD
Regorafenib—CYP2B6—lymphoid tissue—skin cancer	4.67e-05	0.00186	CbGeAlD
Regorafenib—Pain—Temozolomide—skin cancer	4.65e-05	0.0013	CcSEcCtD
Regorafenib—Asthenia—Bleomycin—skin cancer	4.62e-05	0.00129	CcSEcCtD
Regorafenib—Angiopathy—Docetaxel—skin cancer	4.61e-05	0.00129	CcSEcCtD
Regorafenib—Mediastinal disorder—Docetaxel—skin cancer	4.58e-05	0.00128	CcSEcCtD
Regorafenib—ABL1—lymph node—skin cancer	4.53e-05	0.0018	CbGeAlD
Regorafenib—CYP2B6—female reproductive system—skin cancer	4.5e-05	0.00179	CbGeAlD
Regorafenib—Alopecia—Docetaxel—skin cancer	4.49e-05	0.00126	CcSEcCtD
Regorafenib—CYP2C9—female reproductive system—skin cancer	4.46e-05	0.00178	CbGeAlD
Regorafenib—Gastrointestinal pain—Temozolomide—skin cancer	4.44e-05	0.00124	CcSEcCtD
Regorafenib—Malnutrition—Docetaxel—skin cancer	4.43e-05	0.00124	CcSEcCtD
Regorafenib—Decreased appetite—Fluorouracil—skin cancer	4.35e-05	0.00122	CcSEcCtD
Regorafenib—Gastrointestinal disorder—Fluorouracil—skin cancer	4.32e-05	0.00121	CcSEcCtD
Regorafenib—Asthenia—Dactinomycin—skin cancer	4.31e-05	0.0012	CcSEcCtD
Regorafenib—Abdominal pain—Temozolomide—skin cancer	4.29e-05	0.0012	CcSEcCtD
Regorafenib—Body temperature increased—Temozolomide—skin cancer	4.29e-05	0.0012	CcSEcCtD
Regorafenib—Pain—Fluorouracil—skin cancer	4.28e-05	0.0012	CcSEcCtD
Regorafenib—Diarrhoea—Dactinomycin—skin cancer	4.11e-05	0.00115	CcSEcCtD
Regorafenib—Vomiting—Bleomycin—skin cancer	4.09e-05	0.00114	CcSEcCtD
Regorafenib—Anaemia—Docetaxel—skin cancer	4.09e-05	0.00114	CcSEcCtD
Regorafenib—Rash—Bleomycin—skin cancer	4.06e-05	0.00114	CcSEcCtD
Regorafenib—Dermatitis—Bleomycin—skin cancer	4.06e-05	0.00113	CcSEcCtD
Regorafenib—Leukopenia—Docetaxel—skin cancer	3.96e-05	0.00111	CcSEcCtD
Regorafenib—Body temperature increased—Fluorouracil—skin cancer	3.96e-05	0.00111	CcSEcCtD
Regorafenib—Asthenia—Temozolomide—skin cancer	3.9e-05	0.00109	CcSEcCtD
Regorafenib—Nausea—Bleomycin—skin cancer	3.83e-05	0.00107	CcSEcCtD
Regorafenib—Hypertension—Docetaxel—skin cancer	3.82e-05	0.00107	CcSEcCtD
Regorafenib—Vomiting—Dactinomycin—skin cancer	3.82e-05	0.00107	CcSEcCtD
Regorafenib—Rash—Dactinomycin—skin cancer	3.79e-05	0.00106	CcSEcCtD
Regorafenib—CYP2B6—head—skin cancer	3.76e-05	0.0015	CbGeAlD
Regorafenib—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—skin cancer	3.74e-05	0.00105	CcSEcCtD
Regorafenib—Diarrhoea—Temozolomide—skin cancer	3.72e-05	0.00104	CcSEcCtD
Regorafenib—Dry mouth—Docetaxel—skin cancer	3.69e-05	0.00103	CcSEcCtD
Regorafenib—Infection—Docetaxel—skin cancer	3.59e-05	0.001	CcSEcCtD
Regorafenib—Nausea—Dactinomycin—skin cancer	3.57e-05	0.000997	CcSEcCtD
Regorafenib—Nervous system disorder—Docetaxel—skin cancer	3.54e-05	0.00099	CcSEcCtD
Regorafenib—Thrombocytopenia—Docetaxel—skin cancer	3.54e-05	0.000989	CcSEcCtD
Regorafenib—Skin disorder—Docetaxel—skin cancer	3.51e-05	0.000981	CcSEcCtD
Regorafenib—Vomiting—Temozolomide—skin cancer	3.45e-05	0.000966	CcSEcCtD
Regorafenib—Rash—Temozolomide—skin cancer	3.43e-05	0.000958	CcSEcCtD
Regorafenib—Diarrhoea—Fluorouracil—skin cancer	3.42e-05	0.000957	CcSEcCtD
Regorafenib—Dermatitis—Temozolomide—skin cancer	3.42e-05	0.000957	CcSEcCtD
Regorafenib—Headache—Temozolomide—skin cancer	3.4e-05	0.000951	CcSEcCtD
Regorafenib—CYP3A4—female reproductive system—skin cancer	3.4e-05	0.00135	CbGeAlD
Regorafenib—ABCB1—epithelium—skin cancer	3.24e-05	0.00129	CbGeAlD
Regorafenib—Nausea—Temozolomide—skin cancer	3.23e-05	0.000902	CcSEcCtD
Regorafenib—Vomiting—Fluorouracil—skin cancer	3.18e-05	0.00089	CcSEcCtD
Regorafenib—Rash—Fluorouracil—skin cancer	3.16e-05	0.000882	CcSEcCtD
Regorafenib—Dermatitis—Fluorouracil—skin cancer	3.15e-05	0.000882	CcSEcCtD
Regorafenib—Decreased appetite—Docetaxel—skin cancer	3.14e-05	0.000878	CcSEcCtD
Regorafenib—Headache—Fluorouracil—skin cancer	3.14e-05	0.000877	CcSEcCtD
Regorafenib—Gastrointestinal disorder—Docetaxel—skin cancer	3.12e-05	0.000872	CcSEcCtD
Regorafenib—Fatigue—Docetaxel—skin cancer	3.11e-05	0.000871	CcSEcCtD
Regorafenib—Pain—Docetaxel—skin cancer	3.09e-05	0.000864	CcSEcCtD
Regorafenib—Nausea—Fluorouracil—skin cancer	2.97e-05	0.000831	CcSEcCtD
Regorafenib—Gastrointestinal pain—Docetaxel—skin cancer	2.95e-05	0.000826	CcSEcCtD
Regorafenib—Abdominal pain—Docetaxel—skin cancer	2.86e-05	0.000798	CcSEcCtD
Regorafenib—Body temperature increased—Docetaxel—skin cancer	2.86e-05	0.000798	CcSEcCtD
Regorafenib—ABCG2—lymph node—skin cancer	2.85e-05	0.00114	CbGeAlD
Regorafenib—ABCB1—mammalian vulva—skin cancer	2.81e-05	0.00112	CbGeAlD
Regorafenib—Asthenia—Docetaxel—skin cancer	2.59e-05	0.000725	CcSEcCtD
Regorafenib—ABCB1—lymphoid tissue—skin cancer	2.49e-05	0.000994	CbGeAlD
Regorafenib—Diarrhoea—Docetaxel—skin cancer	2.47e-05	0.000691	CcSEcCtD
Regorafenib—ABCB1—female reproductive system—skin cancer	2.41e-05	0.000959	CbGeAlD
Regorafenib—Vomiting—Docetaxel—skin cancer	2.3e-05	0.000642	CcSEcCtD
Regorafenib—Rash—Docetaxel—skin cancer	2.28e-05	0.000637	CcSEcCtD
Regorafenib—Dermatitis—Docetaxel—skin cancer	2.28e-05	0.000636	CcSEcCtD
Regorafenib—Headache—Docetaxel—skin cancer	2.26e-05	0.000633	CcSEcCtD
Regorafenib—Nausea—Docetaxel—skin cancer	2.15e-05	0.0006	CcSEcCtD
Regorafenib—ABCB1—head—skin cancer	2.01e-05	0.000801	CbGeAlD
Regorafenib—ABCB1—lymph node—skin cancer	1.41e-05	0.000561	CbGeAlD
Regorafenib—PDGFRA—Adaptive Immune System—NRAS—skin cancer	2.85e-06	8.36e-05	CbGpPWpGaD
Regorafenib—CYP2C19—Metabolism—CSPG4—skin cancer	2.81e-06	8.26e-05	CbGpPWpGaD
Regorafenib—RAF1—Axon guidance—HRAS—skin cancer	2.76e-06	8.12e-05	CbGpPWpGaD
Regorafenib—MAPK11—Developmental Biology—IL6—skin cancer	2.76e-06	8.09e-05	CbGpPWpGaD
Regorafenib—FGFR2—Innate Immune System—KRAS—skin cancer	2.75e-06	8.06e-05	CbGpPWpGaD
Regorafenib—ABCB1—Metabolism—CSPG4—skin cancer	2.75e-06	8.06e-05	CbGpPWpGaD
Regorafenib—RAF1—Disease—ERCC2—skin cancer	2.75e-06	8.06e-05	CbGpPWpGaD
Regorafenib—FGFR2—Disease—BRAF—skin cancer	2.73e-06	8.01e-05	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—FOXO4—skin cancer	2.7e-06	7.92e-05	CbGpPWpGaD
Regorafenib—KIT—Innate Immune System—KRAS—skin cancer	2.7e-06	7.92e-05	CbGpPWpGaD
Regorafenib—RAF1—Developmental Biology—NRAS—skin cancer	2.7e-06	7.92e-05	CbGpPWpGaD
Regorafenib—KIT—Disease—BRAF—skin cancer	2.68e-06	7.87e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Innate Immune System—NRAS—skin cancer	2.67e-06	7.84e-05	CbGpPWpGaD
Regorafenib—RAF1—Axon guidance—IL6—skin cancer	2.65e-06	7.77e-05	CbGpPWpGaD
Regorafenib—RAF1—Hemostasis—NRAS—skin cancer	2.65e-06	7.77e-05	CbGpPWpGaD
Regorafenib—FLT4—Signaling Pathways—KRAS—skin cancer	2.64e-06	7.74e-05	CbGpPWpGaD
Regorafenib—FGFR2—Adaptive Immune System—KRAS—skin cancer	2.64e-06	7.74e-05	CbGpPWpGaD
Regorafenib—MAPK11—Signaling Pathways—TERT—skin cancer	2.63e-06	7.72e-05	CbGpPWpGaD
Regorafenib—BRAF—Signaling Pathways—TERT—skin cancer	2.6e-06	7.65e-05	CbGpPWpGaD
Regorafenib—ABL1—Innate Immune System—NRAS—skin cancer	2.6e-06	7.64e-05	CbGpPWpGaD
Regorafenib—KIT—Adaptive Immune System—KRAS—skin cancer	2.59e-06	7.6e-05	CbGpPWpGaD
Regorafenib—RAF1—Disease—TERT—skin cancer	2.57e-06	7.55e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Adaptive Immune System—NRAS—skin cancer	2.57e-06	7.53e-05	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism—CSPG4—skin cancer	2.57e-06	7.53e-05	CbGpPWpGaD
Regorafenib—NTRK1—Signaling Pathways—BRAF—skin cancer	2.56e-06	7.52e-05	CbGpPWpGaD
Regorafenib—FGFR1—Innate Immune System—KRAS—skin cancer	2.56e-06	7.51e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Innate Immune System—KRAS—skin cancer	2.55e-06	7.49e-05	CbGpPWpGaD
Regorafenib—FGFR1—Disease—BRAF—skin cancer	2.54e-06	7.47e-05	CbGpPWpGaD
Regorafenib—MAPK11—Innate Immune System—HRAS—skin cancer	2.54e-06	7.46e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Disease—BRAF—skin cancer	2.54e-06	7.45e-05	CbGpPWpGaD
Regorafenib—ABL1—Developmental Biology—KRAS—skin cancer	2.54e-06	7.45e-05	CbGpPWpGaD
Regorafenib—CYP2B6—Metabolism—ENO2—skin cancer	2.53e-06	7.43e-05	CbGpPWpGaD
Regorafenib—ABL1—Hemostasis—KRAS—skin cancer	2.49e-06	7.31e-05	CbGpPWpGaD
Regorafenib—FGFR1—Developmental Biology—HRAS—skin cancer	2.46e-06	7.23e-05	CbGpPWpGaD
Regorafenib—FGFR1—Adaptive Immune System—KRAS—skin cancer	2.46e-06	7.21e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Adaptive Immune System—KRAS—skin cancer	2.45e-06	7.2e-05	CbGpPWpGaD
Regorafenib—MAPK11—Innate Immune System—IL6—skin cancer	2.43e-06	7.14e-05	CbGpPWpGaD
Regorafenib—KDR—Signaling Pathways—BRAF—skin cancer	2.42e-06	7.11e-05	CbGpPWpGaD
Regorafenib—FGFR2—Signaling Pathways—TERT—skin cancer	2.41e-06	7.09e-05	CbGpPWpGaD
Regorafenib—RAF1—Innate Immune System—NRAS—skin cancer	2.38e-06	6.99e-05	CbGpPWpGaD
Regorafenib—BRAF—Disease—PTGS2—skin cancer	2.38e-06	6.98e-05	CbGpPWpGaD
Regorafenib—KIT—Signaling Pathways—TERT—skin cancer	2.37e-06	6.96e-05	CbGpPWpGaD
Regorafenib—UGT1A1—Metabolism—ERCC2—skin cancer	2.36e-06	6.94e-05	CbGpPWpGaD
Regorafenib—UGT1A9—Metabolism—ERCC2—skin cancer	2.36e-06	6.94e-05	CbGpPWpGaD
Regorafenib—FGFR1—Developmental Biology—IL6—skin cancer	2.36e-06	6.92e-05	CbGpPWpGaD
Regorafenib—FLT4—Signaling Pathways—TP53—skin cancer	2.35e-06	6.88e-05	CbGpPWpGaD
Regorafenib—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—skin cancer	2.34e-06	6.87e-05	CbGpPWpGaD
Regorafenib—FGFR2—Innate Immune System—HRAS—skin cancer	2.33e-06	6.85e-05	CbGpPWpGaD
Regorafenib—RAF1—Developmental Biology—KRAS—skin cancer	2.32e-06	6.81e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Innate Immune System—KRAS—skin cancer	2.3e-06	6.75e-05	CbGpPWpGaD
Regorafenib—KIT—Innate Immune System—HRAS—skin cancer	2.29e-06	6.73e-05	CbGpPWpGaD
Regorafenib—FLT1—Signaling Pathways—NRAS—skin cancer	2.29e-06	6.71e-05	CbGpPWpGaD
Regorafenib—RAF1—Adaptive Immune System—NRAS—skin cancer	2.29e-06	6.71e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Disease—BRAF—skin cancer	2.29e-06	6.71e-05	CbGpPWpGaD
Regorafenib—RAF1—Hemostasis—KRAS—skin cancer	2.28e-06	6.68e-05	CbGpPWpGaD
Regorafenib—FGFR1—Signaling Pathways—TERT—skin cancer	2.25e-06	6.6e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—TERT—skin cancer	2.24e-06	6.59e-05	CbGpPWpGaD
Regorafenib—FLT4—Signaling Pathways—HRAS—skin cancer	2.24e-06	6.58e-05	CbGpPWpGaD
Regorafenib—FGFR2—Adaptive Immune System—HRAS—skin cancer	2.24e-06	6.58e-05	CbGpPWpGaD
Regorafenib—ABL1—Innate Immune System—KRAS—skin cancer	2.24e-06	6.58e-05	CbGpPWpGaD
Regorafenib—FGFR2—Innate Immune System—IL6—skin cancer	2.23e-06	6.56e-05	CbGpPWpGaD
Regorafenib—ABL1—Hemostasis—TP53—skin cancer	2.21e-06	6.49e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Adaptive Immune System—KRAS—skin cancer	2.21e-06	6.48e-05	CbGpPWpGaD
Regorafenib—FGFR2—Disease—PTGS2—skin cancer	2.21e-06	6.47e-05	CbGpPWpGaD
Regorafenib—KIT—Adaptive Immune System—HRAS—skin cancer	2.2e-06	6.46e-05	CbGpPWpGaD
Regorafenib—KIT—Innate Immune System—IL6—skin cancer	2.19e-06	6.44e-05	CbGpPWpGaD
Regorafenib—FGFR1—Innate Immune System—HRAS—skin cancer	2.18e-06	6.39e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Innate Immune System—HRAS—skin cancer	2.17e-06	6.37e-05	CbGpPWpGaD
Regorafenib—KIT—Disease—PTGS2—skin cancer	2.17e-06	6.36e-05	CbGpPWpGaD
Regorafenib—ABL1—Developmental Biology—HRAS—skin cancer	2.16e-06	6.33e-05	CbGpPWpGaD
Regorafenib—FLT4—Signaling Pathways—IL6—skin cancer	2.15e-06	6.3e-05	CbGpPWpGaD
Regorafenib—CYP2C8—Metabolism—ENO2—skin cancer	2.14e-06	6.29e-05	CbGpPWpGaD
Regorafenib—ABL1—Hemostasis—HRAS—skin cancer	2.12e-06	6.21e-05	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—PLIN2—skin cancer	2.1e-06	6.16e-05	CbGpPWpGaD
Regorafenib—FGFR1—Adaptive Immune System—HRAS—skin cancer	2.09e-06	6.13e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Adaptive Immune System—HRAS—skin cancer	2.08e-06	6.12e-05	CbGpPWpGaD
Regorafenib—MAPK11—Signaling Pathways—BRAF—skin cancer	2.08e-06	6.11e-05	CbGpPWpGaD
Regorafenib—FGFR1—Innate Immune System—IL6—skin cancer	2.08e-06	6.11e-05	CbGpPWpGaD
Regorafenib—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—skin cancer	2.08e-06	6.11e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Innate Immune System—IL6—skin cancer	2.08e-06	6.1e-05	CbGpPWpGaD
Regorafenib—ABL1—Developmental Biology—IL6—skin cancer	2.06e-06	6.06e-05	CbGpPWpGaD
Regorafenib—FGFR1—Disease—PTGS2—skin cancer	2.06e-06	6.03e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Disease—PTGS2—skin cancer	2.05e-06	6.02e-05	CbGpPWpGaD
Regorafenib—RAF1—Innate Immune System—KRAS—skin cancer	2.05e-06	6.02e-05	CbGpPWpGaD
Regorafenib—RAF1—Disease—BRAF—skin cancer	2.04e-06	5.98e-05	CbGpPWpGaD
Regorafenib—MAPK11—Immune System—NRAS—skin cancer	2.02e-06	5.94e-05	CbGpPWpGaD
Regorafenib—RAF1—Hemostasis—TP53—skin cancer	2.02e-06	5.94e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—TERT—skin cancer	2.02e-06	5.93e-05	CbGpPWpGaD
Regorafenib—ABCG2—Metabolism—ERCC2—skin cancer	2.01e-06	5.89e-05	CbGpPWpGaD
Regorafenib—RAF1—Developmental Biology—HRAS—skin cancer	1.97e-06	5.79e-05	CbGpPWpGaD
Regorafenib—FLT1—Signaling Pathways—KRAS—skin cancer	1.97e-06	5.78e-05	CbGpPWpGaD
Regorafenib—RAF1—Adaptive Immune System—KRAS—skin cancer	1.97e-06	5.78e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Innate Immune System—HRAS—skin cancer	1.95e-06	5.74e-05	CbGpPWpGaD
Regorafenib—RAF1—Hemostasis—HRAS—skin cancer	1.94e-06	5.68e-05	CbGpPWpGaD
Regorafenib—CYP2C19—Metabolism—ENO2—skin cancer	1.91e-06	5.61e-05	CbGpPWpGaD
Regorafenib—FGFR2—Signaling Pathways—BRAF—skin cancer	1.91e-06	5.61e-05	CbGpPWpGaD
Regorafenib—ABL1—Innate Immune System—HRAS—skin cancer	1.91e-06	5.59e-05	CbGpPWpGaD
Regorafenib—RAF1—Developmental Biology—IL6—skin cancer	1.89e-06	5.54e-05	CbGpPWpGaD
Regorafenib—KIT—Signaling Pathways—BRAF—skin cancer	1.88e-06	5.51e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Adaptive Immune System—HRAS—skin cancer	1.88e-06	5.51e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Innate Immune System—IL6—skin cancer	1.87e-06	5.49e-05	CbGpPWpGaD
Regorafenib—ABCB1—Metabolism—ENO2—skin cancer	1.87e-06	5.48e-05	CbGpPWpGaD
Regorafenib—FGFR2—Immune System—NRAS—skin cancer	1.86e-06	5.45e-05	CbGpPWpGaD
Regorafenib—BRAF—Disease—NRAS—skin cancer	1.85e-06	5.43e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Disease—PTGS2—skin cancer	1.85e-06	5.42e-05	CbGpPWpGaD
Regorafenib—KIT—Immune System—NRAS—skin cancer	1.83e-06	5.36e-05	CbGpPWpGaD
Regorafenib—ABL1—Innate Immune System—IL6—skin cancer	1.82e-06	5.35e-05	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—TERT—skin cancer	1.8e-06	5.29e-05	CbGpPWpGaD
Regorafenib—FGFR1—Signaling Pathways—BRAF—skin cancer	1.78e-06	5.23e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—BRAF—skin cancer	1.78e-06	5.22e-05	CbGpPWpGaD
Regorafenib—FLT1—Signaling Pathways—TP53—skin cancer	1.75e-06	5.14e-05	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism—ENO2—skin cancer	1.74e-06	5.12e-05	CbGpPWpGaD
Regorafenib—RAF1—Innate Immune System—HRAS—skin cancer	1.74e-06	5.11e-05	CbGpPWpGaD
Regorafenib—MAPK11—Immune System—KRAS—skin cancer	1.74e-06	5.11e-05	CbGpPWpGaD
Regorafenib—FGFR1—Immune System—NRAS—skin cancer	1.73e-06	5.08e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Immune System—NRAS—skin cancer	1.73e-06	5.07e-05	CbGpPWpGaD
Regorafenib—FGFR2—Disease—NRAS—skin cancer	1.72e-06	5.04e-05	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—CSPG4—skin cancer	1.69e-06	4.97e-05	CbGpPWpGaD
Regorafenib—KIT—Disease—NRAS—skin cancer	1.69e-06	4.95e-05	CbGpPWpGaD
Regorafenib—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—skin cancer	1.68e-06	4.92e-05	CbGpPWpGaD
Regorafenib—FLT1—Signaling Pathways—HRAS—skin cancer	1.67e-06	4.91e-05	CbGpPWpGaD
Regorafenib—RAF1—Adaptive Immune System—HRAS—skin cancer	1.67e-06	4.91e-05	CbGpPWpGaD
Regorafenib—RAF1—Innate Immune System—IL6—skin cancer	1.67e-06	4.9e-05	CbGpPWpGaD
Regorafenib—RAF1—Disease—PTGS2—skin cancer	1.65e-06	4.83e-05	CbGpPWpGaD
Regorafenib—NTRK1—Signaling Pathways—NRAS—skin cancer	1.61e-06	4.73e-05	CbGpPWpGaD
Regorafenib—FLT1—Signaling Pathways—IL6—skin cancer	1.6e-06	4.7e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—BRAF—skin cancer	1.6e-06	4.7e-05	CbGpPWpGaD
Regorafenib—FGFR2—Immune System—KRAS—skin cancer	1.6e-06	4.69e-05	CbGpPWpGaD
Regorafenib—FGFR1—Disease—NRAS—skin cancer	1.6e-06	4.69e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Disease—NRAS—skin cancer	1.6e-06	4.68e-05	CbGpPWpGaD
Regorafenib—BRAF—Disease—KRAS—skin cancer	1.59e-06	4.68e-05	CbGpPWpGaD
Regorafenib—KIT—Immune System—KRAS—skin cancer	1.57e-06	4.61e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Immune System—NRAS—skin cancer	1.56e-06	4.57e-05	CbGpPWpGaD
Regorafenib—KDR—Signaling Pathways—NRAS—skin cancer	1.52e-06	4.47e-05	CbGpPWpGaD
Regorafenib—RAF1—Signaling by GPCR—NRAS—skin cancer	1.52e-06	4.46e-05	CbGpPWpGaD
Regorafenib—ABL1—Immune System—NRAS—skin cancer	1.52e-06	4.45e-05	CbGpPWpGaD
Regorafenib—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—skin cancer	1.5e-06	4.39e-05	CbGpPWpGaD
Regorafenib—FGFR1—Immune System—KRAS—skin cancer	1.49e-06	4.38e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Immune System—KRAS—skin cancer	1.49e-06	4.36e-05	CbGpPWpGaD
Regorafenib—MAPK11—Immune System—HRAS—skin cancer	1.48e-06	4.35e-05	CbGpPWpGaD
Regorafenib—FGFR2—Disease—KRAS—skin cancer	1.48e-06	4.33e-05	CbGpPWpGaD
Regorafenib—CYP2B6—Metabolism—ERCC2—skin cancer	1.47e-06	4.31e-05	CbGpPWpGaD
Regorafenib—KIT—Disease—KRAS—skin cancer	1.45e-06	4.26e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Disease—NRAS—skin cancer	1.44e-06	4.22e-05	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—BRAF—skin cancer	1.43e-06	4.19e-05	CbGpPWpGaD
Regorafenib—MAPK11—Immune System—IL6—skin cancer	1.42e-06	4.16e-05	CbGpPWpGaD
Regorafenib—UGT1A1—Metabolism—PTGS2—skin cancer	1.42e-06	4.16e-05	CbGpPWpGaD
Regorafenib—UGT1A9—Metabolism—PTGS2—skin cancer	1.42e-06	4.16e-05	CbGpPWpGaD
Regorafenib—RAF1—Immune System—NRAS—skin cancer	1.39e-06	4.07e-05	CbGpPWpGaD
Regorafenib—NTRK1—Signaling Pathways—KRAS—skin cancer	1.39e-06	4.07e-05	CbGpPWpGaD
Regorafenib—FGFR1—Disease—KRAS—skin cancer	1.38e-06	4.04e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Disease—KRAS—skin cancer	1.37e-06	4.03e-05	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—skin cancer	1.36e-06	4e-05	CbGpPWpGaD
Regorafenib—FGFR2—Immune System—HRAS—skin cancer	1.36e-06	3.99e-05	CbGpPWpGaD
Regorafenib—BRAF—Disease—HRAS—skin cancer	1.35e-06	3.98e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Immune System—KRAS—skin cancer	1.34e-06	3.93e-05	CbGpPWpGaD
Regorafenib—KIT—Immune System—HRAS—skin cancer	1.34e-06	3.92e-05	CbGpPWpGaD
Regorafenib—KDR—Signaling Pathways—KRAS—skin cancer	1.31e-06	3.84e-05	CbGpPWpGaD
Regorafenib—MAPK11—Signaling Pathways—NRAS—skin cancer	1.31e-06	3.84e-05	CbGpPWpGaD
Regorafenib—RAF1—Signaling by GPCR—KRAS—skin cancer	1.31e-06	3.84e-05	CbGpPWpGaD
Regorafenib—ABL1—Immune System—KRAS—skin cancer	1.31e-06	3.83e-05	CbGpPWpGaD
Regorafenib—FGFR2—Immune System—IL6—skin cancer	1.3e-06	3.82e-05	CbGpPWpGaD
Regorafenib—BRAF—Signaling Pathways—NRAS—skin cancer	1.3e-06	3.81e-05	CbGpPWpGaD
Regorafenib—BRAF—Disease—IL6—skin cancer	1.3e-06	3.8e-05	CbGpPWpGaD
Regorafenib—RAF1—Disease—NRAS—skin cancer	1.28e-06	3.76e-05	CbGpPWpGaD
Regorafenib—KIT—Immune System—IL6—skin cancer	1.28e-06	3.75e-05	CbGpPWpGaD
Regorafenib—FGFR1—Immune System—HRAS—skin cancer	1.27e-06	3.72e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Immune System—HRAS—skin cancer	1.26e-06	3.71e-05	CbGpPWpGaD
Regorafenib—FGFR2—Disease—HRAS—skin cancer	1.26e-06	3.68e-05	CbGpPWpGaD
Regorafenib—CYP2C8—Metabolism—ERCC2—skin cancer	1.24e-06	3.65e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Disease—KRAS—skin cancer	1.24e-06	3.63e-05	CbGpPWpGaD
Regorafenib—KIT—Disease—HRAS—skin cancer	1.23e-06	3.62e-05	CbGpPWpGaD
Regorafenib—NTRK1—Signaling Pathways—TP53—skin cancer	1.23e-06	3.62e-05	CbGpPWpGaD
Regorafenib—FGFR1—Immune System—IL6—skin cancer	1.21e-06	3.56e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Immune System—IL6—skin cancer	1.21e-06	3.55e-05	CbGpPWpGaD
Regorafenib—ABCG2—Metabolism—PTGS2—skin cancer	1.2e-06	3.53e-05	CbGpPWpGaD
Regorafenib—FGFR2—Signaling Pathways—NRAS—skin cancer	1.2e-06	3.53e-05	CbGpPWpGaD
Regorafenib—FGFR2—Disease—IL6—skin cancer	1.2e-06	3.53e-05	CbGpPWpGaD
Regorafenib—RAF1—Immune System—KRAS—skin cancer	1.19e-06	3.5e-05	CbGpPWpGaD
Regorafenib—KIT—Signaling Pathways—NRAS—skin cancer	1.18e-06	3.46e-05	CbGpPWpGaD
Regorafenib—KIT—Disease—IL6—skin cancer	1.18e-06	3.46e-05	CbGpPWpGaD
Regorafenib—NTRK1—Signaling Pathways—HRAS—skin cancer	1.18e-06	3.46e-05	CbGpPWpGaD
Regorafenib—FGFR1—Disease—HRAS—skin cancer	1.17e-06	3.43e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Disease—HRAS—skin cancer	1.17e-06	3.43e-05	CbGpPWpGaD
Regorafenib—KDR—Signaling Pathways—TP53—skin cancer	1.16e-06	3.42e-05	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—ENO2—skin cancer	1.15e-06	3.38e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Immune System—HRAS—skin cancer	1.14e-06	3.34e-05	CbGpPWpGaD
Regorafenib—NTRK1—Signaling Pathways—IL6—skin cancer	1.13e-06	3.31e-05	CbGpPWpGaD
Regorafenib—MAPK11—Signaling Pathways—KRAS—skin cancer	1.13e-06	3.31e-05	CbGpPWpGaD
Regorafenib—FGFR1—Signaling Pathways—NRAS—skin cancer	1.12e-06	3.29e-05	CbGpPWpGaD
Regorafenib—FGFR1—Disease—IL6—skin cancer	1.12e-06	3.29e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—NRAS—skin cancer	1.12e-06	3.28e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Disease—IL6—skin cancer	1.12e-06	3.28e-05	CbGpPWpGaD
Regorafenib—BRAF—Signaling Pathways—KRAS—skin cancer	1.12e-06	3.28e-05	CbGpPWpGaD
Regorafenib—KDR—Signaling Pathways—HRAS—skin cancer	1.11e-06	3.27e-05	CbGpPWpGaD
Regorafenib—CYP2C19—Metabolism—ERCC2—skin cancer	1.11e-06	3.26e-05	CbGpPWpGaD
Regorafenib—RAF1—Signaling by GPCR—HRAS—skin cancer	1.11e-06	3.26e-05	CbGpPWpGaD
Regorafenib—ABL1—Immune System—HRAS—skin cancer	1.11e-06	3.26e-05	CbGpPWpGaD
Regorafenib—RAF1—Disease—KRAS—skin cancer	1.1e-06	3.24e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Immune System—IL6—skin cancer	1.09e-06	3.2e-05	CbGpPWpGaD
Regorafenib—ABCB1—Metabolism—ERCC2—skin cancer	1.08e-06	3.18e-05	CbGpPWpGaD
Regorafenib—KDR—Signaling Pathways—IL6—skin cancer	1.07e-06	3.13e-05	CbGpPWpGaD
Regorafenib—RAF1—Signaling by GPCR—IL6—skin cancer	1.06e-06	3.12e-05	CbGpPWpGaD
Regorafenib—ABL1—Immune System—IL6—skin cancer	1.06e-06	3.12e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Disease—HRAS—skin cancer	1.05e-06	3.09e-05	CbGpPWpGaD
Regorafenib—FGFR2—Signaling Pathways—KRAS—skin cancer	1.03e-06	3.04e-05	CbGpPWpGaD
Regorafenib—KIT—Signaling Pathways—KRAS—skin cancer	1.02e-06	2.98e-05	CbGpPWpGaD
Regorafenib—RAF1—Immune System—HRAS—skin cancer	1.01e-06	2.98e-05	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism—ERCC2—skin cancer	1.01e-06	2.97e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—NRAS—skin cancer	1.01e-06	2.95e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Disease—IL6—skin cancer	1.01e-06	2.95e-05	CbGpPWpGaD
Regorafenib—MAPK11—Signaling Pathways—TP53—skin cancer	1e-06	2.94e-05	CbGpPWpGaD
Regorafenib—BRAF—Signaling Pathways—TP53—skin cancer	9.92e-07	2.91e-05	CbGpPWpGaD
Regorafenib—RAF1—Immune System—IL6—skin cancer	9.71e-07	2.85e-05	CbGpPWpGaD
Regorafenib—FGFR1—Signaling Pathways—KRAS—skin cancer	9.64e-07	2.83e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—KRAS—skin cancer	9.61e-07	2.82e-05	CbGpPWpGaD
Regorafenib—MAPK11—Signaling Pathways—HRAS—skin cancer	9.57e-07	2.81e-05	CbGpPWpGaD
Regorafenib—BRAF—Signaling Pathways—HRAS—skin cancer	9.48e-07	2.78e-05	CbGpPWpGaD
Regorafenib—RAF1—Disease—HRAS—skin cancer	9.37e-07	2.75e-05	CbGpPWpGaD
Regorafenib—FGFR2—Signaling Pathways—TP53—skin cancer	9.19e-07	2.7e-05	CbGpPWpGaD
Regorafenib—MAPK11—Signaling Pathways—IL6—skin cancer	9.16e-07	2.69e-05	CbGpPWpGaD
Regorafenib—BRAF—Signaling Pathways—IL6—skin cancer	9.08e-07	2.66e-05	CbGpPWpGaD
Regorafenib—KIT—Signaling Pathways—TP53—skin cancer	9.03e-07	2.65e-05	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—NRAS—skin cancer	8.97e-07	2.63e-05	CbGpPWpGaD
Regorafenib—RAF1—Disease—IL6—skin cancer	8.97e-07	2.63e-05	CbGpPWpGaD
Regorafenib—CYP2B6—Metabolism—PTGS2—skin cancer	8.81e-07	2.59e-05	CbGpPWpGaD
Regorafenib—FGFR2—Signaling Pathways—HRAS—skin cancer	8.79e-07	2.58e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—KRAS—skin cancer	8.66e-07	2.54e-05	CbGpPWpGaD
Regorafenib—KIT—Signaling Pathways—HRAS—skin cancer	8.63e-07	2.53e-05	CbGpPWpGaD
Regorafenib—FGFR1—Signaling Pathways—TP53—skin cancer	8.57e-07	2.51e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—TP53—skin cancer	8.54e-07	2.51e-05	CbGpPWpGaD
Regorafenib—FGFR2—Signaling Pathways—IL6—skin cancer	8.41e-07	2.47e-05	CbGpPWpGaD
Regorafenib—KIT—Signaling Pathways—IL6—skin cancer	8.26e-07	2.43e-05	CbGpPWpGaD
Regorafenib—FGFR1—Signaling Pathways—HRAS—skin cancer	8.19e-07	2.4e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—HRAS—skin cancer	8.17e-07	2.4e-05	CbGpPWpGaD
Regorafenib—FGFR1—Signaling Pathways—IL6—skin cancer	7.84e-07	2.3e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—IL6—skin cancer	7.82e-07	2.3e-05	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—KRAS—skin cancer	7.72e-07	2.27e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—TP53—skin cancer	7.7e-07	2.26e-05	CbGpPWpGaD
Regorafenib—CYP2C8—Metabolism—PTGS2—skin cancer	7.46e-07	2.19e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—HRAS—skin cancer	7.36e-07	2.16e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—IL6—skin cancer	7.05e-07	2.07e-05	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—TP53—skin cancer	6.86e-07	2.01e-05	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—ERCC2—skin cancer	6.68e-07	1.96e-05	CbGpPWpGaD
Regorafenib—CYP2C19—Metabolism—PTGS2—skin cancer	6.66e-07	1.96e-05	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—HRAS—skin cancer	6.56e-07	1.93e-05	CbGpPWpGaD
Regorafenib—ABCB1—Metabolism—PTGS2—skin cancer	6.5e-07	1.91e-05	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—IL6—skin cancer	6.28e-07	1.84e-05	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism—PTGS2—skin cancer	6.07e-07	1.78e-05	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—PTGS2—skin cancer	4.01e-07	1.18e-05	CbGpPWpGaD
